Dose-Finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine will be investigated in healthy children aged 6 to 16 years.
| Condition | Intervention | Phase |
|---|---|---|
|
Tick-Borne Encephalitis |
Biological: Tick-borne encephalitis vaccine |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Prevention |
| Official Title: | Double-Blind, Randomized, Multicenter Dose-Finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years. |
Eligibility| Ages Eligible for Study: | 6 Years to 15 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Male and female children will be eligible for participation in this study if:
- they are 6 years (from the 6th birthday) to 16 years old (to the last day before the 16th birthday);
- they are clinically healthy;
- their legal representative – and if older than 8 years the volunteer - understands the nature of the study, agrees to its provisions and gives written informed consent;
- their legal representative agrees to keep a Volunteer Diary.
For safety reasons female volunteers capable of bearing children have to fulfill the following inclusion criteria at study start:
- negative pregnancy test at study start;
- they agree to employ adequate birth control measures for the duration of the study.
Exclusion Criteria:
Children will be excluded from participation in this study if they:
- have a history of any previous TBE vaccination;
- have a history of TBE infection or show evidence of a latent TBE infection (as demonstrated by screening ELISA > 126 VIEU/ml and / or neutralization test > 1:10);
- have a history of allergic reactions, in particular to one of the components of the vaccine;
- have received antipyretics within 4 hours prior to the first TBE vaccination;
- suffer from a disease that cannot be effectively treated or stabilized;
- suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment that can be expected to influence immunological functions;
- suffer from chronic, degenerative and / or inflammatory disease of the central nervous system;
- are known to be HIV positive (a special HIV test is not required for the purpose of the study);
- suffer from a febrile illness at study entry;
- have a history of vaccination against yellow fever and / or Japanese B-encephalitis;
- are participating simultaneously in another clinical trial.
- if female, are pregnant or breast feeding
Volunteers who meet the inclusion / exclusion criteria, but have a febrile illness (body temperature >= 38° C, measured orally) at the scheduled time of vaccination, will not be vaccinated before their body temperature returns to normal.
Contacts and Locations| Germany | |
| Neuschwansteinstrasse 5 | |
| Augsburg, Germany, 86163 | |
| Marktplatz 33 | |
| Bad Saulgau, Germany, 88348 | |
| Hauptstrasse 9 | |
| Bietigheim-Bissingen, Germany, 74321 | |
| Salzgasse 11 | |
| Calw, Germany, 75365 | |
| Mohrenstrasse 8 | |
| Coburg, Germany, 96450 | |
| Bahnhofstrasse 1 | |
| Elzach, Germany, 79215 | |
| Rheinstrasse 13 | |
| Ettenheim, Germany, 77955 | |
| Peter-Seifert Strasse 5 | |
| Gersfeld, Germany, 36129 | |
| Solothurner Strasse 2 | |
| Heilbronn, Germany, 74072 | |
| Hauptstraße 240 | |
| Kehl, Germany, 77694 | |
| Schwarzwaldstrasse 20 | |
| Kirchzarten, Germany, 79199 | |
| Altoettingerstrasse 3 | |
| Landsberg, Germany, 86899 | |
| Rastatter Strasse 7 | |
| Mannheim-Secken, Germany, 68239 | |
| Wilhelmstrasse 25 | |
| Metzingen, Germany, 72555 | |
| Heubischer Strasse 39 | |
| Neustadt/Cbg, Germany, 96465 | |
| Dohmbuehlerstrasse 8 | |
| Nürnberg, Germany, 90449 | |
| Schwarzwaldstrasse 18 | |
| Oberkirch, Germany, 77704 | |
| Asternweg 11a | |
| Offenburg, Germany, 77656 | |
| Wilhelmstrasse 7 | |
| Offenburg, Germany, 77654 | |
| Bergstrasse 27 | |
| Rottweil, Germany, 78628 | |
| Berneckstrasse 19 | |
| Schrammberg, Germany, 78713 | |
| Hauptstrasse 11 | |
| Tegernsee, Germany, 83681 | |
| Broner Platz 6 | |
| Weingarten, Germany, 88250 | |
| Principal Investigator: | Ulrich Behre, MD | Hauptstrasse 240, 77694 Kehl, Germany |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00161798 History of Changes |
| Other Study ID Numbers: | 205 |
| Study First Received: | September 8, 2005 |
| Last Updated: | June 12, 2006 |
| Health Authority: | Germany: Paul-Ehrlich-Institut |
Additional relevant MeSH terms:
|
Encephalitis Encephalitis, Tick-Borne Central Nervous System Viral Diseases Virus Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Central Nervous System Infections |
Encephalitis, Arbovirus Arbovirus Infections Tick-Borne Diseases Encephalitis, Viral RNA Virus Infections Flavivirus Infections Flaviviridae Infections |
ClinicalTrials.gov processed this record on June 17, 2013